Table 1 Clinical and laboratory characteristics of the CRC, the RCC and the LCC
Characteristic | ALL | Training Cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|---|
Number (%) | Number (%) | Number (%) | |||||
ALL | RCC | LCC | RCC | LCC | RCC | LCC | |
Age, years | |||||||
  < 59 | 972 (52.7%) | 427 (43.9%) | 545 (56.1%) | 220 (44.1%) | 279 (55.9%) | 207 (43.8%) | 266 (56.2%) |
  ≥ 59 | 874 (47.3%) | 317 (36.3%) | 557 (63.7%) | 162 (38.2%) | 262 (61.8%) | 155 (34.4%) | 295 (65.6%) |
Sex | |||||||
 Male | 1106 (59.9%) | 431 (39.0%) | 675 (61.0%) | 227 (39.6%) | 346 (60.4%) | 204 (38.3%) | 329 (61.7%) |
 Female | 740 (40.1%) | 313 (42.3%) | 427 (57.7%) | 155 (44.3%) | 195 (55.7%) | 158 (40.5%) | 232 (59.5%) |
CRP, mg/L | |||||||
  < 3.26 | 923 (50.0%) | 312 (33.8%) | 611 (66.2%) | 160 (37.1%) | 271 (62.9%) | 152 (30.9% | 340 (69.1%) |
  ≥ 3.26 | 923 (50.0%) | 432 (46.8%) | 491 (53.2%) | 222 (45.1%) | 270 (54.9%) | 210 (48.7%) | 221 (51.3%) |
WBCs, ×109 | |||||||
  < 6.4 | 934 (50.6%) | 363 (38.9%) | 571 (61.1%) | 178 (39.2%) | 276 (60.8%) | 185 (38.5% | 295 (61.5%) |
  ≥ 6.4 | 912 (49.4%) | 381 (41.8%) | 531 (58.2%) | 204 (43.5%) | 265 (56.5%) | 177 (40.0%) | 266 (60.0%) |
Neutrophils, ×109 | |||||||
  < 3.9 | 928 (50.3%) | 349 (37.6%) | 579 (62.4%) | 178 (40.4%) | 263 (48.6%) | 171 (35.1%) | 316 (64.9%) |
  ≥ 3.9 | 918 (49.7% | 395 (43.0%) | 523 (57.0%) | 204 (42.3%) | 278 (57.7%) | 191 (43.8%) | 245 (56.2%) |
Platelets, ×109 | |||||||
  < 252 | 933 (50.5%) | 294 (31.5%) | 639 (68.5%) | 157 (33.2%) | 316 (66.8%) | 137 (29.8%) | 323 (70.2%) |
  ≥ 252 | 913 (49.5%) | 450 (49.3%) | 463 (50.7%) | 225 (50.0%) | 225 (50.0%) | 225 (48.6%) | 238 (51.4%) |
ALB, g/L | |||||||
  < 40.5 | 924 (50.1%) | 431 (46.6%) | 493 (53.4%) | 217 (45.4%) | 261 (54.6%) | 214 (48.0%) | 232 (52.0%) |
  ≥ 40.5 | 922 (49.9%) | 313 (33.9%) | 609 (66.1%) | 165 (37.1%) | 280 (62.9%) | 148 (31.0%) | 329 (69.0%) |
CEA, ng/mL | |||||||
  < 5 | 1066 (57.7%) | 443 (41.6%) | 623 (58.4%) | 270 (40.8%) | 392 (59.2%) | 218 (37.8%) | 359 (62.2%) |
  ≥ 5 | 780 (42.3%) | 301 (38.6%) | 479 (61.4%) | 112 (42.9%) | 149 (57.1%) | 144 (41.6%) | 202 (58.4%) |
CA199, U/mL | |||||||
  < 27 | 1361 (73.7%) | 536 (39.4%) | 825 (60.6%) | 270 (40.8%) | 392 (59.2%) | 266 (38.1%) | 433 (61.9%) |
  ≥ 27 | 485 (27.3%) | 208 (42.9%) | 277 (57.1%) | 112 (42.9%) | 149 (57.1%) | 96 (42.9%) | 128 (57.1%) |
T lymphocytes, ×109 | |||||||
  < 1.6 | 939 (50.9%) | 399 (42.5%) | 540 (57.5%) | 202 (42.7%) | 271 (57.3%) | 197 (42.3%) | 269 (57.7%) |
  ≥ 1.6 | 907 (49.1%) | 345 (38.0%) | 562 (62.0%) | 180 (40.0%) | 270 (60.0%) | 165 (36.1%) | 292 (63.9%) |
Monocytes, ×109 | |||||||
  < 0.4 | 951 (51.5%) | 382 (40.2%) | 569 (59.8%) | 206 (41.5%) | 299 (58.5%) | 176 (39.7%) | 279 (61.3%) |
  ≥ 0.4 | 895 (48.5%) | 362 (40.4%) | 533 (59.6%) | 176 (41.2%) | 251 (58.8%) | 186 (39.7%) | 282 (60.3%) |
MMR | |||||||
 D-MMR | 1613 (87.4%) | 588 (36.5%) | 1025 (63.5%) | 93 (66.0%) | 48 (34.0%) | 63 (68.5%) | 29 (31.5%) |
 P-MMR | 233 (12.6%) | 156 (67.0%) | 77 (33.0%) | 289 (37.0%) | 493 (63.0%) | 299 (36.0%) | 532 (64.0%) |
TNM category | |||||||
 Chemotherapy | |||||||
  No | 231 (12.5%) | 101 (10.6%) | 130 (14.5%) | 71 (12.7%) | 40 (10.9%) | 60 (11.8%) | 60 (14.5%) |
  Yes | 1499 (81.2%) | 799 (84.1%) | 700 (78.1%) | 429 (77.0%) | 300 (82.0%) | 430 (84.3%) | 340 (82.3%) |
  Unknown | 116 (6.3%) | 50 (5.3%) | 66 (7.4%) | 57 (10.2%) | 26 (7.1%) | 20 (3.9%) | 13 (3.1%) |
 Radiotherapy | |||||||
  No | 1322 (71.6%) | 611 (70.1%) | 711 (73.0%) | 411 (74.5%) | 250 (67.4%) | 355 (65.7%) | 306 (79.9%) |
  Yes | 378 (20.5%) | 191 (21.9%) | 187 (19.2%) | 111 (20.1%) | 78 (21.0%) | 145 (26.9%) | 44 (11.5%) |
  Unknown | 146 (7.9%) | 70 (8.0%) | 76 (7.8%) | 30 (5.4%) | 43 (11.6%) | 40 (7.4%) | 33 (8.6%) |
 TNM category | |||||||
  1 | 168 (9.1%) | 34 (20.2%) | 134 (79.8%) | 15 (20.8%) | 57 (79.2%) | 19 (19.8%) | 77 (80.2%) |
  2 | 839 (45.4%) | 376 (44.8%) | 463 (55.2%) | 176 (47.8%) | 192 (52.2%) | 200 (42.5%) | 271 (57.5%) |
  3 | 518 (28.1%) | 202 (39.0%) | 316 (61.0%) | 100 (39.8%) | 151 (60.2%) | 102 (38.2%) | 165 (61.8%) |
  4 | 321 (17.4%) | 132 (41.1%) | 189 (58.9%) | 91 (39.2%) | 141 (60.8%) | 41 (46.1%) | 48 (53.9%) |
 PLR |  | 744 | 1102 |  |  |  |  |
   < 154.96 | 923 (50.0%) | 295 (32.0%) | 628 (68.0%) | 160 (34.2%) | 308 (65.8% | 135 (29.7%) | 320 (70.3%) |
   ≥ 154.96 | 923 (50.0%) | 449 (48.6%) | 474 (51.4%) | 222 (48.8%) | 233 (51.2%) | 227 (48.5%) | 241 (51.5%) |
 NLR | |||||||
   < 2.35 | 923 (50.0%) | 330 (35.8%) | 593 (64.2%) | 165 (37.1%) | 280 (62.9%) | 165 (34.5%) | 313 (65.5%) |
   ≥ 2.35 | 923 (50.0%) | 414 (44.9%) | 509 (55.1%) | 217 (45.4%) | 261 (54.6%) | 197 (44.3%) | 248 (55.7%) |
 PNI |  | 744 | 1102 |  |  |  |  |
   < 48.88 | 921 (49.9%) | 363 (39.4%) | 558 (60.6%) | 182 (40.1%) | 272 (59.9%) | 181 (38.8%) | 286 (61.2%) |
   ≥ 48.88 | 925 (50.1% | 381 (41.2%) | 544 (58.8%) | 200 (42.6%) | 269 (57.4%) | 181 (39.7%) | 275 (60.3%) |
 CAR |  | 744 | 1102 |  |  |  |  |
   < 0.08 | 923 (50.0%) | 306 (33.2%) | 617 (66.8%) | 157 (36.3%) | 275 (63.7%) | 149 (30.3%) | 342 (69.7%) |
   ≥ 0.08 | 923 (50.0%) | 438 (47.5%) | 485 (52.5%) | 225 (45.8%) | 266 (54.2%) | 213 (49.3%) | 219 (50.7%) |
 mGPS | |||||||
  0 | 1243 (67.3%) | 441 (35.5%) | 802 (64.5%) | 223 (37.5%) | 371 (62.5%) | 218 (33.6%) | 431 (66.4%) |
  1 | 406 (22.0%) | 200 (49.3%) | 206 (50.7%) | 114 (50.2%) | 113 (49.8%) | 86 (48.0%) | 93 (52.0%) |
  2 | 197 (10.7%) | 103 (52.3%) | 94 (47.7%) | 45 (44.1%) | 57 (55.9% | 58 (61.1%) | 37 (38.9%) |
 Survival status | |||||||
  Live | 1586 (85.9%) | 660 (41.6%) | 926 (58.4%) | 316 (44.4%) | 396 (55.6%) | 344 (39.4%) | 530 (60.6%) |
  Dead | 260 (14.1%) | 84 (32.3%) | 176 (67.7%) | 66 (31.3%) | 145 (68.7%) | 18 (36.7%) | 31 (63.3%) |